Literature DB >> 10434875

Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy.

G Smith1, D McLeod, D Foreman, M Boulton.   

Abstract

AIM: To determine the spatial and temporal changes in the staining pattern of the VEGF receptors FLT-1, KDR, and the putative receptor FLT-4 during the pathogenesis of diabetic retinopathy.
METHODS: Immunohistochemical localisation of VEGF receptors, using antibodies against FLT-1, FLT-4, and KDR, was carried out on specimens of normal human retina (n = 10), diabetic retinas (a) with no overt retinopathy (n = 12), (b) with intraretinal vascular abnormalities but no proliferative retinopathy (n = 5), (c) with active proliferative retinopathy (n = 6), and (d) with no residual proliferative retinopathy after scatter photocoagulation therapy (n = 14), and surgically excised diabetic fibrovascular membranes (n = 11). The degree and pattern of immunostaining was recorded.
RESULTS: FLT-1 staining was apparent in the retinas from both non-diabetic and diabetic retinas; weak to moderate staining was generally confined to the inner nuclear layer, the ganglion cell layer, and the retinal vessels during all stages of the disease process. Staining of the retinal vessels was raised in diabetic tissue compared with non-diabetic tissue. The preretinal vessels of the diabetic subjects stained moderately to intensely for FLT-1. In contrast with FLT-1 staining minimal immunostaining for KDR was demonstrated in the non-diabetic eyes and the unlasered eyes; however, weak staining for KDR was observed in the inner nuclear layer and the ganglion cell layer of the unlasered eyes with diabetic changes. In those retinas with preretinal neovascularisation KDR immunoreactivity was moderate to intense in the intra- and preretinal vessels. However, in the excised membranes, where the vessels may have been in a quiescent state, the levels of KDR were weak to moderate. After apparently successful laser treatment KDR staining was reduced in the intraretinal vessels. Minimal FLT-4 staining was observed throughout normal eyes while weak to moderate FLT-4 staining was generally confined to the inner nuclear layer and the ganglion cell layer of the unlasered diabetic eyes. Weak to moderate levels of FLT-4 staining were observed in the intraretinal vessels except after apparently successful laser treatment where reduced levels of staining were observed. Weak to moderate staining was observed in the preretinal vessels.
CONCLUSIONS: This study supports a role for FLT-1, KDR, and possibly FLT-4 in the pathogenesis of diabetic retinopathy; however, their specific roles in the progression of the disease may differ.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434875      PMCID: PMC1722996          DOI: 10.1136/bjo.83.4.486

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  52 in total

Review 1.  Vascular endothelial growth factor. The trigger for neovascularization in the eye.

Authors:  N Ferrara
Journal:  Lab Invest       Date:  1995-06       Impact factor: 5.662

2.  Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.

Authors:  L F Brown; S M Olbricht; B Berse; R W Jackman; G Matsueda; K A Tognazzi; E J Manseau; H F Dvorak; L Van de Water
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

3.  Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.

Authors:  J Pe'er; D Shweiki; A Itin; I Hemo; H Gnessin; E Keshet
Journal:  Lab Invest       Date:  1995-06       Impact factor: 5.662

4.  Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels.

Authors:  T Murata; T Ishibashi; A Khalil; Y Hata; H Yoshikawa; H Inomata
Journal:  Ophthalmic Res       Date:  1995       Impact factor: 2.892

5.  Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

Authors:  C A Boocock; D S Charnock-Jones; A M Sharkey; J McLaren; P J Barker; K A Wright; P R Twentyman; S K Smith
Journal:  J Natl Cancer Inst       Date:  1995-04-05       Impact factor: 13.506

6.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Authors:  E A Pierce; R L Avery; E D Foley; L P Aiello; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

Review 7.  The role of vascular endothelial growth factor in pathological angiogenesis.

Authors:  N Ferrara
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

8.  VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor.

Authors:  B Terman; L Khandke; M Dougher-Vermazan; D Maglione; N J Lassam; D Gospodarowicz; M G Persico; P Böhlen; M Eisinger
Journal:  Growth Factors       Date:  1994       Impact factor: 2.511

9.  Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro.

Authors:  M Guerrin; H Moukadiri; P Chollet; F Moro; K Dutt; F Malecaze; J Plouët
Journal:  J Cell Physiol       Date:  1995-08       Impact factor: 6.384

10.  Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia.

Authors:  J Stone; A Itin; T Alon; J Pe'er; H Gnessin; T Chan-Ling; E Keshet
Journal:  J Neurosci       Date:  1995-07       Impact factor: 6.167

View more
  14 in total

Review 1.  Glucose, VEGF-A, and diabetic complications.

Authors:  L E Benjamin
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Early trials of angiogenic factors have not targeted patients most at risk of ocular disease.

Authors:  M McKibbin; D O'Neill
Journal:  BMJ       Date:  1999-09-04

Review 3.  The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.

Authors:  G B Arden
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

4.  Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2.

Authors:  Bojun Zhao; Gill Smith; Jun Cai; Aihua Ma; Mike Boulton
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

5.  Multiple receptor tyrosine kinases are expressed in adult rat retinal ganglion cells as revealed by single-cell degenerate primer polymerase chain reaction.

Authors:  Niclas Lindqvist; Ulrika Lönngren; Marta Agudo; Ulla Näpänkangas; Manuel Vidal-Sanz; Finn Hallböök
Journal:  Ups J Med Sci       Date:  2010-02       Impact factor: 2.384

Review 6.  A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage.

Authors:  David McLeod
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

Review 7.  Vascular endothelial growth factor in eye disease.

Authors:  J S Penn; A Madan; R B Caldwell; M Bartoli; R W Caldwell; M E Hartnett
Journal:  Prog Retin Eye Res       Date:  2008-05-28       Impact factor: 21.198

Review 8.  Arginase in retinopathy.

Authors:  S Priya Narayanan; Modesto Rojas; Jutamas Suwanpradid; Haroldo A Toque; R William Caldwell; Ruth B Caldwell
Journal:  Prog Retin Eye Res       Date:  2013-07-03       Impact factor: 21.198

9.  Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation.

Authors:  Xiufeng Zhong; Hu Huang; Jikui Shen; Serena Zacchigna; Lorena Zentilin; Mauro Giacca; Stanley A Vinores
Journal:  Mol Vis       Date:  2011-02-17       Impact factor: 2.367

10.  Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

Authors:  Jian Hua Qi; Quteba Ebrahem; Mariya Ali; Alecia Cutler; Brent Bell; Nicholas Prayson; Jonathan Sears; Vera Knauper; Gillian Murphy; Bela Anand-Apte
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.